Introduction
The first hematopoietic cell transplants (HCT) with durable success in humans were reported in 1968 in three patients with primary immunodeficiencies (PIDs) who received grafts from HLA-matched siblings. Significant progress has been made with HCT for PID over the past 40 years, allowing the vast majority of children with PID, worldwide, access to relatively well-matched and safer procedures to correct their otherwise lethal disorders. Important advances include broader availability of high-resolution tissue typing, establishment of cooperating unrelated donor registries around the globe and development of chemotherapeutic and immunosuppressive pre-transplant conditioning regimens associated with significantly reduced early posttransplant mortality. With the definition of the genetic bases of the majority of lethal PIDs, more accurate studies of the natural history of the disorders have become possible and provide a compelling rationale for early transplantation in PIDs with median survival of 15-20 years. The major obstacles to successful long-term, high-quality survival and immuno-reconstitution for patients with PID are (1) delayed diagnosis and (2) treatment in centers lacking expertise in the management of patients with PIDs.
Delays in diagnosis of the PID, or delays in proceeding to HCT, frequently result in the emergence of pretransplant morbidities, including opportunistic infections, exposure to herpes viruses and development of autoimmune complications-all of which can compromise the likelihood of long-term success with HCT.
In the current era, HCT using HLA-identical healthy sibling donors can provide correction of underlying PIDs such as SCIDs, Wiskott-Aldrich syndrome (WAS) and other prematurely lethal X-linked immunodeficiencies in approximately 90% of the cases. In some conditions, the availability of closely matched unrelated donors (adult marrow or umbilical cord blood) can provide similarly beneficial results. For patients with genetically determined immune/inflammatory disorders such as hemophagocytic lymphohistiocytosis (HLH) and other disorders of immune homeostasis, the current results with HCT are less favorable, with 5-year disease-free survival rates closer to 60-70%.
Hematopoietic cell transplant for SCIDs
SCID represents a group of genetically distinct birth defects manifested by severely depressed humoral and cellmediated immunity, with extreme susceptibility to death from infection, in the first months to years of life. HCT remains the only potentially curative therapy for the majority of patients with SCID. Most patients with SCID lack closely matched family donors and are treated with HCT from alternative related or unrelated donors. Despite 40 years of experience, no clear consensus has emerged regarding preferred alternative donor source or conditioning regimens for patients with SCID. Registry data from the European Blood and Marrow Transplant network and the Center for International Blood and Marrow Transplantation (CIBMTR) indicate that the underlying genotype/phenotype of SCID, in aggregate, predicts early (1-3 years) survival, with better results seen in TÀB þ NKÀ forms and worst outcomes in adenosine deaminase deficiency (ADA), especially with the use of unrelated donors. Young age at transplant (under 1 year, and preferably in the first several weeks) results in improved recovery, survival and immune reconstitution. 1 Historically, T-depleted grafts from haploidentical parents were the major donor source in patients with SCID lacking matched sibling donors, and pre-transplant conditioning was not used. According to the European series of 475 patients collected between 1968 and 1999, survival rates for all SCID phenotypes combined ranged from approximately 80% with matched sibling donors to 50% with haploidentical donors, with transplants from unrelated donors at approximately 70%.
2 CIBMTR data from 1990 to 2004 (748 patients) reveal very similar rates of survival according to donor source. Many patients in these series were treated at a time when quantitation of CD34 cells was not available or not routinely performed, and tests of posttransplant immune reconstitution were quite primitive. The long-term follow-up of 38 patients surviving more than 5 years after one or more haploidentical grafts presented from the Necker Hospital in Paris, France, at the 2006 meeting of the European Society for Immunodeficiency (ESID) reveals the consequences of poor engraftment and incomplete immuno-reconstitution: persistent need for IgG replacement, opportunistic infections (especially with papillomavirus 3 ) chronic GVHD, autoimmunity and late deaths. 4 In that analysis, event-free survival for the overall group of haploidentical graft recipients was 50%, whereas patients with the common g-chain deficiency (X-SCID) or JAK3 deficiency had reduced long-term survival of 20%.
In contrast, the more recent experience in 30 patients from Toronto, Canada, using closely matched unrelated donors and myeloablative conditioning (BU, cytoxan and anti-thymocyte globulin) has resulted in a 76% overall survival, including 8 of 9 patients with X-SCID. 5 Despite the high incidence of acute GVHD (24/30 patients), patients who are off immune suppression no longer require IgG replacement, and maintain TRECs (T-cell receptor excision circles, DNA episomes in newly formed T cells) within normal range for age. Clearly, longer follow-up of this patient group is needed to assess incidence of any late sequelae.
Hematopoietic cell transplant for prematurely lethal X-linked immunodeficiencies
Prior to 1990, transplants for many of the X-linked disorders, specifically WAS, X-linked hyper IgM syndrome and chronic granulomatous disease, were restricted to patients with matched sibling donors and often to patients who had already suffered life-threatening complications from their diseases. More recently, with the publication of successful transplants using closely matched unrelated donors, many more boys and young men with these conditions are being treated with HCTs, and at younger ages. Although rates of GVHD appear higher in the recipients of unrelated grafts, this complication is better tolerated in children than adults, and with careful attention can often be entirely ameliorated.
Median survival for WAS has been reported from the US NIH series as 15 years of age. The impact of donor type on transplants for WAS was first compared in a study from the CIBMTR of 170 patients. 6 In that study, survival after matched sibling transplant was 87% compared with recipients of unrelated donor grafts for whom its was 70%, or other related donors (including haploidentical grafts)-for whom it was 52%. Among the group of patients treated with unrelated donor BMT, boys transplanted under 5 years of age had a survival rate similar to those receiving matched sibling grafts. In contrast, use of unrelated donor transplants in older patients (often with significant comorbities) resulted in long-term survival rates of less than 30%. A more recent analysis from the CIBMTR comparing 113 recipients of unrelated bone marrow with 65 patients who received unrelated cord blood transplants shows equivalent survival 3 years post transplant for recipients under 5 years of age at the time of the procedure (73 and 75%). As correction of all aspects of WAS requires myeloid and lymphoid engraftment, to date the vast majority of transplant patients with WAS has been conditioned with myeloablative protocols. Despite full donor engraftment, use of unrelated donor transplants in WAS can be complicated by autoimmune cytopenias, particularly during the first year post transplant even in the absence of evident GVHD. Thus, close follow-up by the transplant center should continue for at least the first 2 years after grafting.
Less experience has been published regarding X-linked Hyper IgM syndrome (XHIM or CD40 ligand deficiency). For X-linked Hyper IgM syndrome, the European experience suggests that 40-50% of patients can survive into the third decade. However, many patients develop chronic morbidities in the first decade, including neutropenia, lung damage and liver dysfunction. The retrospective analysis of 38 HCT for X-linked Hyper IgM syndrome performed in eight European countries determined that 58% of patients (72% of those without liver disease) had been cured. In that series, 22 patients received unrelated donor grafts. 7 Preexisting lung disease was the most significant adverse risk factor.
The prognosis for longevity and quality of life with chronic granulomatous disease is highly variable. A number of successful transplants with matched sibling donors and myeloablative therapy have been published, including treatment of patients with serious pre-existing infections. 8 Results with a less intensive preparative regimen used in a US NIH study indicated a significant rate of poor engraftment in children, and is now generally avoided.
X-linked lymphoproliferative syndrome can lead to fulminant EBV infection, lymphomas, hypogammaglobulinemia and other autoimmune and inflammatory complications. Median survival has been reported as less than 10 years. Patients with X-linked lymphoproliferative syndrome have received transplantation at various stages of their disease. 9 However, given that the most frequent fatal complication is a rapidly progressive, EBV-driven process similar to HLH, allogeneic HCT should be recommended for symptomatic and asymptomatic patients.
Hematopoietic cell transplant for two other prematurely lethal X-linked disorders that have recently been defined on a molecular level, that is, IPEX (immune dysregulation polyendocrinopathy, X-linked) 10 and NEMO-ID (NF-kB Essential Modifier with immunodeficiency), is still in its infancy. Longer follow-up is needed to judge which features of these disorders may be permanently reversible.
Hematopoietic cell transplant for immune/inflammatory disorders
Primary HLH is a rapidly progressing lethal inflammatory disorder, which results from failure of immunoregulatory mechanisms in the immune system and can lead to multiorgan failure if not treated promptly. Several autosomal recessive genetic causes, all related to the function of the perforin-dependent cytotoxic pathway, have been identified in affected patients. However, worldwide, the genetic defects underlying a majority of HLH cases are still unknown. Treatment of HLH consists of two phases. The first is induction therapy aimed at achieving clinical remission from inflammation and it's sequelae, including hepatosplenomegaly, cytopenias, fevers, and hepatic, pulmonary and CNS dysfunction. The second, definitive, phase is immunological correction by HCT. In a recently conducted international trial, post-transplant survival at 3 years was shown to be approximately 70% for recipients of matched sibling or matched unrelated donor HCT.
11
Recipients of mismatched family donor grafts had an inferior survival rate of approximately 50%. For children who have experienced CNS involvement with HLH, posttransplant neurocognitive complications may persist; however, a majority of survivors enjoy a good quality of life.
Patients with a related disorder, Chediak-Higashi syndrome, also frequently develop an HLH reaction, especially after exposure to EBV. Other abnormalities in the Chediak-Higashi syndrome include hematological abnormalities involving several lineages, occulocutaneous pseudoalbinism and progressive, but variable, neurological deficits. The recently published CIBMTR review of HCT discussed 34 patients, 20 of whom had experienced a lifethreatening 'accelerated phase' (HLH) prior to HCT. 12 Three-year disease-free survival rates were 79% for HLAidentical sibling transplants, 67% with matched unrelated donor transplants and 30% with alternative related donor HCT. A retrospective review of long-term survivors of HCT for the Chediak-Higashi syndrome from France cautions that significant neurological deficits may exist or progress later in life, despite stable hematological correction. 13 
Remaining challenges
Pre-existing morbidities and infections are the principal adverse risk factors for poor outcomes with HCT, and post-transplant infections are the major cause of death in HCT for PID. To improve on current results with HCT for PID, several aspects should be considered: (1) earlier diagnosis, (2) sufficient, well-tolerated pre-transplant conditioning regimens, (3) preemptive infectious surveillance and (4) promotion of immuno-reconsitution.
Early (presymptomatic) diagnosis, especially for patients affected with SCID, has the potential to significantly improve their outcomes. In the so-called developed countries where birth rates are relatively low and families are widely dispersed, many cases of SCID are diagnosed sporadically, often after the child has experienced a lifethreatening complication. Proposals to screen neonates for SCID could reverse this problem. In the United States, blood spots routinely collected at birth for all newborns were used to test the hypothesis that quantitation of TRECs could identify patients with a wide variety of SCID genotypes.
14 Compared with normal infants, in whom more than 1000 TRECs were typically detected in two 3-mm punches, 23 infants with different forms of SCID had o30 TRECs.
Pre-transplant conditioning protocols should be adequate to ensure durable engraftment, yet are relatively nontoxic. While avoidance of any preparative regimen has long been attractive for patients with SCID, careful review of immunological recovery reveals that, in a majority of cases, long-term immuno-reconsitution is only partial. This appears to be particularly the case with recipients of manipulated (that is, T-depleted) grafts or grafts from non-HLA-identical sibling donors. Even gene therapy for SCID requires some facilitation with chemotherapy prior to infusion of genetically corrected autologous stem cells.
Currently, there is much interest in the so-called reducedintensity conditioning regimens, which rely on intense immune suppression and less on myelotoxicity. 15 As more rare PID disorders (SCID and CID) are recognized as genetically 'radiosensitive', avoidance of radiation and radiomimetic drugs is particularly important. Reducedintensity conditioning regimens typically include fludara-bine and anti-T-cell biologics such as anti-thymocyte globulin or anti CD52 humanized monoclonal antibody (Campath). In some PIDs, including SCID, HLH and IPEX, this approach has appeared useful, while in others (such as chronic granulomatous disease) it has failed due to graft rejection or waning chimerism. The search for the 'perfect' approach to conditioning patients with PID continues.
Preemptive infectious surveillance has vastly improved in recent years, with PCR-based techniques being used more widely to track viral and fungal acquisition or reactivation in post-BMT patients.
Promotion of immuno-reconstitution remains a significant obstacle to the recovery of patients undergoing HCT for PID. Poor or absent pre-transplant thymic function along with prolonged use of GVHD-preventive and GVHD-suppressive medications delays recovery of lymphocytes required for adequate control of viral infections in particular, and predisposes to autoimmune complications in the early months and years after grafting. In SCID, very early grafting (less than 1 month) with T-depleted or Treplete, fully matched grafts has been associated with more rapid and robust immune recovery. 1 A recent review of long-term survivors following HCT for SCID from Holland concluded that early recovery of TRECs was most predictive of functional T-cell reconstitution for the long term, and that poor T-cell reconstitution (for example, poor grafts) predicted later problems. 16 Thus, use of this analyte sequentially may prove instructive in defining which patients might benefit from HCT 'boosts' in the early months or years after primary HCT.
